SELLAS Life Sciences Group, Inc.
Moat Score — SELLAS Life Sciences Group, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | SELLAS holds exclusive licenses to galinpepimut-S (from Memorial Sloan Kettering) and SLS009 (from GenFleet Therapeutics), plus FDA Orphan Drug and Fast Track designations on SLS009 that confer real regulatory exclusivity. These are genuine legal and scientific barriers, but both assets remain unapproved and unproven commercially, so the intangible value is still largely potential rather than realized. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | SELLAS has no manufacturing scale, no commercial infrastructure, and no product revenue to amortize costs against. As a clinical-stage licensor rather than a low-cost producer, it has no basis for a cost advantage versus any competitor. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, SELLAS has no current pricing power. If galinpepimut-S is approved as a first-to-market maintenance therapy in second-complete-remission AML, it could command strong pricing in the absence of a direct competitor, but this is speculative until REGAL reads out. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | SELLAS's pipeline is built on peptide immunotherapy and a CDK9 inhibitor, neither of which generates any network effect — there is no mechanism by which additional patients, prescribers, or data materially increase the product's value to new users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | There is no approved product in use today, so no prescriber or patient switching cost yet exists. If galinpepimut-S launches into an AML maintenance niche with no approved alternative, oncologists who establish a treatment pattern around it could become modestly resistant to switching once a competitor eventually emerges, but this is not yet a realized advantage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The AML maintenance-therapy niche that galinpepimut-S targets is narrow and currently has no approved occupant, which could support efficient-scale economics for an early entrant, but the market is still unproven in size and SELLAS has no operating scale of any kind today. |